EcoDrugPlus

Ribosomal Protein L18

Ensembl ID : ENSDARG00000029533
Gene Symbol: RPL18
12 Enzyme and pathways 5 Cross references
380 Possible Orthologues:

Ribosomal Protein L18a

Ensembl ID : ENSDARG00000025073
Gene Symbol: RPL18A
12 Enzyme and pathways 5 Cross references
366 Possible Orthologues:

Ribosomal Protein L19

Ensembl ID : ENSDARG00000013307
Gene Symbol: RPL19
12 Enzyme and pathways 5 Cross references
354 Possible Orthologues:

Ribosomal Protein L21

Ensembl ID : ENSDARG00000010516
Gene Symbol: RPL21
12 Enzyme and pathways 5 Cross references
783 Possible Orthologues:

Ribosomal Protein L22

Ensembl ID : ENSDARG00000070437
Gene Symbol: RPL22
12 Enzyme and pathways 5 Cross references
384 Possible Orthologues:

Ribosomal Protein L23

Ensembl ID : ENSDARG00000053457
Gene Symbol: RPL23
12 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Ribosomal Protein L23a

Ensembl ID : ENSDARG00000006316
Gene Symbol: RPL23A
12 Enzyme and pathways 5 Cross references
819 Possible Orthologues:

Ribosomal Protein L24

Ensembl ID : ENSDARG00000099104
Gene Symbol: RPL24
12 Enzyme and pathways 5 Cross references
322 Possible Orthologues:

Ribosomal Protein L26

Ensembl ID : ENSDARG00000102317
Gene Symbol: RPL26
12 Enzyme and pathways 5 Cross references
477 Possible Orthologues:

Ribosomal Protein L27

Ensembl ID : ENSDARG00000015128
Gene Symbol: RPL27
12 Enzyme and pathways 5 Cross references
371 Possible Orthologues:

Ribosomal Protein L28

Ensembl ID : ENSDARG00000005791
Gene Symbol: RPL28
12 Enzyme and pathways 5 Cross references
283 Possible Orthologues:

Ribosomal Protein L29

Ensembl ID : ENSDARG00000077717
Gene Symbol: RPL29
12 Enzyme and pathways 5 Cross references
505 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).